Equities

Recro Pharma Inc

REPH:NAQ

Recro Pharma Inc

Actions
  • Price (USD)16.86
  • Today's Change-0.600 / -3.44%
  • Shares traded403.72k
  • 1 Year change140.86%
  • Beta-0.3787
Data delayed at least 15 minutes, as of Nov 12 2019 21:00 GMT.
More ▼

Events & Activity

  • REPH:NAQ reported earnings of -0.19 for the period of the year 2019Q3.
  • REPH:NAQ price reached a new 52-week high of 16.86 at 09:32 GMT
  • REPH:NAQ price moved over +4.07% to 16.35
  • REPH:NAQ trading volume exceeds daily average by +15.28%

Key statistics

On Tuesday, Recro Pharma Inc (REPH:NAQ) closed at 16.86, -5.60% below its 52-week high of 17.86, set on Nov 08, 2019.
52-week range
Today
5.53Mar 25 201917.86Nov 08 2019
Markit short selling activity
Low
Med
High
Open17.46
High17.66
Low16.75
Bid13.98
Offer18.00
Previous close17.46
Average volume423.45k
Shares outstanding22.73m
Free float22.08m
P/E (TTM)--
Market cap396.87m USD
EPS (TTM)-2.33
USD
Data delayed at least 15 minutes, as of Nov 12 2019 21:00 GMT.
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.